Supernus Pharmaceuticals Inc

SUPN

Market Cap$1.6B

Close$

Compare Supernus Pharmaceuticals

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Supernus Pharmaceuticals Inc	-103.4	0%	-2%	2.9	-
Market Avg	54.3	1.27%	32%	-	1.3
Healthcare Avg	39.1	1.36%	17%	7.2	1.3

$39.00

Target Price by Analysts

33.7% upsideSupernus Pharmaceuticals Target Price Details

$75.71

Current Fair Value

159.6% upside

Undervalued by 159.6% based on the discounted cash flow analysis.

Share Statistics

Market cap	$1.60 Billion
Enterprise Value	$1.31 Billion
Dividend Yield	$0.0 (0.0%)
Earnings per Share	$-0.29
Beta	0.83
Outstanding Shares	54,974,254
Avg 30 Day Volume	462,487

Return

Return on Equity	-
Return on Assets	-
Return on Invested Capital	-

Valuation & Multiples

P/E Ratio	-103.37
PEG	104.13
Price to Sales	2.92
Price to Book Ratio	1.82
Enterprise Value to Revenue	2.18
Enterprise Value to EBIT	232.01
Enterprise Value to Net Income	-85
Total Debt to Enterprise	0
Debt to Equity	0

Revenue Sources

No data

ESG Score

No data

About Supernus Pharmaceuticals Inc

CEO: Jack Khattar